Laboratory correlates in multiple myeloma: how useful for prognosis?
- 30 June 2001
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 15 (2) , 97-102
- https://doi.org/10.1054/blre.2001.0154
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridizationBlood, 2000
- Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in MyelomaCancer Genetics and Cytogenetics, 1999
- Prognostic value of cytogenetics in multiple myelomaBritish Journal of Haematology, 1998
- Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.Journal of Clinical Oncology, 1997
- Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.Journal of Clinical Oncology, 1994
- Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]Blood, 1993
- Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.Journal of Clinical Oncology, 1991
- Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myelomaBlood, 1988
- The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosisBlood, 1985
- Ploidy and proliferative characteristics in monoclonal gammopathiesBlood, 1982